The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Abbvie; Celgene/Bristol-Myers Squibb; Janssen; Jazz Pharmaceuticals
Research Funding - Abbvie (Inst); Celgene/Bristol-Myers Squibb (Inst); Janssen (Inst); Jazz Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Jazz Pharmaceuticals
Longer-term RBC transfusion reduction in the phase III MEDALIST study of luspatercept in patients (pts) with lower-risk MDS with ring sideroblasts (RS).
 
Rami S. Komrokji
Stock and Other Ownership Interests - Abbvie
Consulting or Advisory Role - agios; Celgene; Daiichi Sankyo; incyte; Janssen; Novartis; Pfizer
Speakers' Bureau - Alexion Pharmaceuticals; Jazz Pharmaceuticals; Novartis
Travel, Accommodations, Expenses - Alexion Pharmaceuticals; Celgene; Daiichi Sankyo; Incyte; Jazz Pharmaceuticals; Novartis
 
Mikkael A. Sekeres
Consulting or Advisory Role - Celgene; Millennium; Syros Pharmaceuticals
Research Funding - Pfizer (Inst); Takeda (Inst)
 
Amer Methqal Zeidan
Honoraria - Abbvie; Acceleron Pharma; Agios; Astellas Pharma; BeyondSpring Pharmaceuticals; Boehringer Ingelheim; Bristol-Myers Squibb; Cardinal Health; Celgene; Daiichi Sankyo; Epizyme; Incyte; Ions Pharmaceuticals; Jazz Pharmaceuticals; Novartis; Otsuka; Pfizer; Seagen; Taiho Pharmaceutical; Takeda; Trovagene
Consulting or Advisory Role - Abbvie; Acceleron Pharma; Agios; Astellas Pharma; BeyondSpring Pharmaceuticals; Boehringer Ingelheim; Bristol-Myers Squibb; Cardinal Health; Celgene; Daiichi Sankyo; Epizyme; Incyte; Ions Pharmaceuticals; Jazz Pharmaceuticals; Novartis; Otsuka; Pfizer; Seagen; Taiho Pharmaceutical; Takeda; Trovagene
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); Aprea AB (Inst); Astex Pharmaceuticals (Inst); AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Incyte (Inst); Novartis (Inst); Pfizer (Inst); Takeda (Inst); Trovagene (Inst)
Travel, Accommodations, Expenses - Celgene; Novartis; Pfizer; Trovagene
 
Pierre Fenaux
No Relationships to Disclose
 
Alan F. List
Honoraria - Aileron Therapeutics; Celgene; Cellular Biomedicine Group
Consulting or Advisory Role - Acceleron Pharma; Aileron Therapeutics; Celgene; Cellular Biomedicine Group; International Personalized Cancer Center
Research Funding - Celgene
Travel, Accommodations, Expenses - Celgene; Cellular Biomedicine Group
Other Relationship - Thousand Talents Award
 
Amy Elizabeth Dezern
Consulting or Advisory Role - Celgene
Research Funding - Astex Pharmaceuticals (Inst); celgene (Inst)
Travel, Accommodations, Expenses - Abbvie
 
Peter L. Greenberg
Stock and Other Ownership Interests - Amgen; Celgene/Bristol-Myers Squibb
Consulting or Advisory Role - Novartis
Research Funding - Aprea Therapeutics (Inst); Celgene/Bristol-Myers Squibb (Inst); Genentech (Inst); H3 Biomedicine (Inst); Notable Labs (Inst); Novartis (Inst)
 
Michael R. Savona
Stock and Other Ownership Interests - Karyopharm Therapeutics
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Karyopharm Therapeutics; Merck; Ryvu Therapeutics; TG Therapeutics
Research Funding - Astex Pharmaceuticals (Inst); Incyte (Inst); Sunesis Pharmaceuticals (Inst); Takeda (Inst); TG Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Product license - Boehringer-Ingelheim (minority owner)
 
Joseph G. Jurcic
Consulting or Advisory Role - Abbvie; AstraZeneca; Boston Biomedical; Celgene; Daiichi Sankyo; Novartis
Research Funding - Abbvie (Inst); Actinium Pharmaceuticals (Inst); Arog (Inst); Astellas Pharma (Inst); Celgene (Inst); Daiichi Sankyo (Inst); FORMA Therapeutics (Inst); Genentech (Inst); Kura Oncology (Inst); PTC Therapeutics (Inst); Syros Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Abbvie; Bristol-Myers Squibb; Celgene
(OPTIONAL) Uncompensated Relationships - Actinium Pharmaceuticals
 
Amit Verma
Stock and Other Ownership Interests - Stelexis Therapeutics
Honoraria - Acceleron Pharma; Celgene; Stelexis Therapeutics
Research Funding - Bristol-Myers Squibb (Inst); Janssen Oncology (Inst)
 
Ghulam J. Mufti
Consulting or Advisory Role - Abbvie; Novartis
Research Funding - Celgene/Bristol-Myers Squibb (Inst); Novartis (Inst)
 
Rena Buckstein
Honoraria - Celgene/Bristol-Myers Squibb
Consulting or Advisory Role - Celgene/Bristol-Myers Squibb
Research Funding - Celgene/Bristol-Myers Squibb (Inst); Otsuka (Inst)
 
Valeria Santini
Honoraria - Celgene/Bristol-Myers Squibb; Johnson & Johnson; Novartis
Consulting or Advisory Role - Acceleron Pharma; Amgen; Celgene/Bristol-Myers Squibb; Menarini; Novartis
 
Abderrahmane Laadem
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Rodrigo Ito
Employment - Bayer (I); Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Jennie Zhang
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Chrystal Ursula Louis
Employment - Bristol-Myers Squibb; Celgene
Stock and Other Ownership Interests - Bristol-Myers Squibb; Celgene
Patents, Royalties, Other Intellectual Property - Celgene/Bristol-Myers Squibb; Cell Medica; Merrimack
 
Peter G. Linde
Employment - Acceleron Pharma
Stock and Other Ownership Interests - Abbott; Abbvie; Acceleron Pharma; FibroGen
Patents, Royalties, Other Intellectual Property - Acceleron Pharma
 
Guillermo Garcia-Manero
Honoraria - Abbvie; Acceleron Pharma; Astex Pharmaceuticals; Celgene; Helsinn Healthcare
Consulting or Advisory Role - Acceleron Pharma; Astex Pharmaceuticals; Bristol-Myers Squibb; Celgene; Helsinn Therapeutics; Jazz Pharmaceuticals
Research Funding - Abbvie; Amphivena; Astex Pharmaceuticals; Bristol-Myers Squibb; celgene; H3 Biomedicine; Helsinn Therapeutics; Merck; Novartis; Onconova Therapeutics